Who
Julia P. Gregory
Director
Company insider
Files Form 4 as: Director, Nurix Therapeutics; Director, Biohaven; Director, Biohaven Pharmaceutical Holding Co; CEO, Contrafect; EVP and CFO, Lexicon Pharmaceuticals.
In numbers
- Trades disclosed
- 62
- Buys
- 2
- Sells
- 7
- Bought
- $154K
- Sold
- $4.5M
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 30 Dec 2005
- Last trade
- 14 Oct 2026
- Last filed
- 14 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 Oct 2026filed 14 Oct 2026 | NRIX Nurix TherapeuticsBiotechnology | SEC FORM 4 Code M | $42K22,583 at $1.86 | filing |
| 14 Oct 2026filed 14 Oct 2026 | NRIX Nurix TherapeuticsBiotechnology | SEC FORM 4 Sold | $529K22,583 at $23.40 | filing |
| 14 Oct 2026filed 14 Oct 2026 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —22,583 at $0.00 | filing |
| 15 May 2026filed 15 May 2026 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,250 at $0.00 | filing |
| 15 May 2026filed 15 May 2026 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,250 at $0.00 | filing |
| 28 Apr 2026filed 30 Apr 2026 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code A | —68,693 at $0.00 | filing |
| 28 Apr 2026filed 30 Apr 2026 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code A | —68,693 at $0.00 | filing |
| 17 Sep 2025filed 17 Sep 2025 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,750 at $0.00 | filing |
| 17 Sep 2025filed 17 Sep 2025 | NRIX Nurix TherapeuticsBiotechnology | SEC FORM 4 Code M | $20K10,750 at $1.86 | filing |
| 19 May 2025filed 19 May 2025 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 5 May 2025filed 7 May 2025 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,716 at $0.00 | filing |
| 20 May 2024filed 20 May 2024 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 30 Apr 2024filed 2 May 2024 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,592 at $0.00 | filing |
| 4 May 2023filed 4 May 2023 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 2 May 2023filed 4 May 2023 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code A | —52,906 at $0.00 | filing |
| 25 Oct 2022filed 26 Oct 2022 | BHVN BiohavenBiotechnology | SEC FORM 4 Bought | $100K9,523 at $10.50 | filing |
| 3 Oct 2022filed 5 Oct 2022 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code J | —4,119 | filing |
| 3 Oct 2022filed 5 Oct 2022 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code J | —5,998 | filing |
| 3 Oct 2022filed 5 Oct 2022 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code J | —9,000 | filing |
| 3 Oct 2022filed 5 Oct 2022 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code J | —9,000 | filing |
News
Nurix Therapeutics (NASDAQ:NRIX) Director Julia Gregory Sells 22,583 Shares of Company StockNRIX · dailypolitical.com · 15 Oct 2026Nurix Therapeutics Q3 2026 Earnings: Key Financials RevealedNRIX · sci-tech-today.com · 13 Oct 2026Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateNRIX · manilatimes.net · 12 Oct 2026
0 headlines in the last 90 days name Julia P. Gregory; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.